Chediak-Higashi syndrome (CHS) is invariably fatal if left untreated; patients usually die during the accelerated phase, which in many ways resembles familial hemophagocytic lymphohistiocytosis (FHLH). Eapen et al.
1 recently published the results of a multi-institutional study of 35 patients with CHS who underwent allogeneic stem cell transplantation (SCT); they reported an overall survival rate of 62%. This survival rate is comparable to that reported in patients with FHLH post-allogeneic SCT as shown recently by Ouache´e-Chardin et al.
2 in a group of 58 FHLH patients, where the patients received etoposide in addition to busulfan and cyclophosphamide in the preparative regimen; the overall survival rate was 58.5%.
In the study by Eapen et al., 1 the combination of busulfan and cyclophosphamide was the most common preparative regimen, but some patients received etoposide in addition; the authors correlated the survival and disease status post-SCT with some pre-transplant factors such as disease status pre-transplant and donor type, but they did not address the impact of the conditioning regimen (namely with or without etoposide) on the outcome, although on the other hand the small number of patients in each group (with or without etoposide) in that study may not have allowed such an analysis.
The success of etoposide in inducing remission in patients with familial hemophagocytic syndrome pre-SCT has been reproduced in patients with CHS experiencing accelerated phase; 3 this led many transplanters to incorporate etoposide in the conditioning regimen for these patients. Haddad et al. 4 reported 10 patients with CHS who underwent allogeneic SCT; 9 of them received etoposide for their conditioning as well as busulfan and cyclophosphamide; a total of 7 patients were alive and well at the time of the report. In the same way, we used busulfan, cyclophosphamide and etoposide at our institution on five patients with CHS who underwent allogeneic SCT between April 2001 and May 2005; two patients received antithymocyte globulins in addition. Three had fully matched donors (siblings), one had a one-antigen-mismatched donor (maternal aunt) and one received a one-antigenmismatched unrelated cord blood. Four patients presented with accelerated phase and were treated with etoposide and steroids, and all patients were in remission at the time of SCT. Four patients engrafted; engraftment was documented by donor-recipient chimerism studies and ranged between 10 and 100% donor chimerism. One patient subsequently lost his graft and died of disease recurrence 14 months after SCT. There were two additional deaths; one was 7 months post-SCT because of sepsis, but the patient was in remission at the time of death, and one was in the recipient of the unrelated cord blood who died of intracranial hemorrhage on day 38 post-SCT before engraftment. Two patients remain alive and free of disease at 5.5 and 4 years, respectively. Obviously, our numbers are also too small to make any solid conclusion about the effect of etoposide on the eventual results.
Therefore, although etoposide had a dramatic impact on the management of the accelerated phase in CHS patients, its role in the conditioning of such patients before allogeneic SCT is yet to be validated; in fact, the rarity of the disease would be a major limitation for any study trying to address this issue, and thus the answer to this question remains elusive. 
